内科理论与实践 ›› 2021, Vol. 16 ›› Issue (01): 37-44.doi: 10.16138/j.1673-6087.2021.01.009
收稿日期:
2020-09-16
出版日期:
2021-02-25
发布日期:
2022-07-26
通讯作者:
高丰厚
E-mail:fenghougao@163.com
基金资助:
CHEN Chen, YIN Shanshan, GUO Jiahui, GAO Fenghou()
Received:
2020-09-16
Online:
2021-02-25
Published:
2022-07-26
Contact:
GAO Fenghou
E-mail:fenghougao@163.com
摘要:
目的:探索微RNA(microRNA,miRNA/miR)-29家族对淋巴结侵袭性非小细胞肺癌(non-small cell lung cancer,NSCLC)细胞增殖、侵袭的影响及潜在的分子机制。方法:TCGA数据库分析磷酸酶和张力蛋白同源基因(phosphatase and tension homology deleted from chromosome 10, PTEN)mRNA在是否有淋巴结转移的NSCLC患者组织中的表达水平;蛋白质印迹检测非淋巴结转移NSCLC细胞A549以及淋巴结转移NSCLC细胞H1299中PTEN蛋白水平;生物信息学预测调节PTEN的miRNA,实时定量反转录PCR(quantitative reverse transcriptase-mediated PCR,qRT-PCR)检测miR-29家族在A549和H1299中的表达水平;生物信息学预测miR-29家族与PTEN mRNA 3’ 非翻译区(untranslated region,UTR)结合位点,且通过双荧光素酶报告基因系统验证;转染miR a/b/c类似物或者抑制子,蛋白质印迹检测细胞中PTEN蛋白表达水平;用CRISPR Cas9技术构建miR-29家族敲低的稳转细胞;蛋白质印迹检测磷酸化Akt(phosphorylated Akt,p-Akt)、Akt、磷酸化黏着斑激酶(phosphorylated focal adhesion kinase,p-FAK)、FAK表达水平,qRT-PCR检测存活蛋白mRNA表达水平以及蛋白质印迹检测存活蛋白;细胞活力检测试剂盒(cell counting kit-8,CCK-8)检测细胞增殖及Transwell检测细胞侵袭的改变。结果:TCGA数据库分析PTEN mRNA的均值在无淋巴结转移NSCLC患者癌组织中表达高于有淋巴结转移的患者(7.916比7.242,P=0.026 8);PTEN蛋白在A549细胞表达水平高于H1299细胞(3.1倍);而在H1299细胞中miR-29家族分别是A549细胞的4、4.4和4.1倍(P<0.01);荧光素酶报告基因实验验证了miR-29家族可靶向结合PTEN mRNA 3’UTR区的位点。A549细胞转染miR a/b/c类似物 36 h后,PTEN蛋白表达水平下降,H1299细胞转染miR a/b/c 抑制子 36 h后,PTEN蛋白表达分别恢复25%、21%和62%。与对照组相比,敲低miR-29家族后H1299细胞中p-Akt与p-FAK水平降低,存活蛋白 mRNA水平下调35%以及蛋白表达水平也相应下调70%;敲低miR-29家族后H1299细胞增殖活性下降,同时细胞的侵袭能力降低75%。结论:NSCLC细胞中miR-29家族通过下调PTEN,致p-Akt、p-FAK信号通路异常活化,进而上调存活蛋白表达,促进NSCLC细胞增殖和淋巴结侵袭。
中图分类号:
陈晨, 尹姗姗, 郭佳慧, 高丰厚. 微RNA-29家族降解PTEN mRNA促进非小细胞肺癌细胞存活与淋巴结侵袭[J]. 内科理论与实践, 2021, 16(01): 37-44.
CHEN Chen, YIN Shanshan, GUO Jiahui, GAO Fenghou. Degradation of PTEN mRNA by microRNA-29 family promotes survival and lymph node invasion of non-small cell lung cancer cell[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(01): 37-44.
图2
miR-29与PTEN mRNA 3’-UTR相互作用情况 A:PTEN mRNA 3’-UTR、676~682位点突变的MT1、1 741~1 747位点突变的MT2以及双位点突变的MT1+2被分别插入双荧光素酶报告质粒,即psiCHECK2- PTEN 3’-UTR-WT、psiCHECK2- PTEN 3’-UTR MT1、psiCHECK2- PTEN 3’-UTR MT2和psiCHECK2- PTEN 3’-UTR MT1+2; B:psiCHECK2- PTEN 3’-UTR-WT、psiCHECK2- PTEN 3’-UTR MT1、psiCHECK2- PTEN 3’-UTR MT2和psiCHECK2- PTEN 3’-UTR MT1+2分别与NC或miR-29a/b/c类似物共同转染293T细胞,24 h后收集细胞,测定R/F比值;C:NC或miR-29a/b/c类似物转染NSCLCA549细胞36 h,蛋白质印迹检测PTEN蛋白的表达水平,GAPDH为内参;D:NC或miR-29a/b/c 抑制子转染淋巴结侵袭性NSCLC H1299细胞36 h,蛋白质印迹检测PTEN蛋白的表达水平,GAPDH为内参
图3
敲低侵袭性H1299细胞中miR-29后对PTEN磷酸酶活性的影响 在淋巴结侵袭性NSCLC H1299细胞中通过CRISPR Cas9技术敲低H1299细胞中的miR-29a/b/c后,A:qRT-PCR检测细胞中miR-29a/b/c mRNA的相对表达水平,以U6为内参;B:qRT-PCR检测细胞中PTEN mRNA的相对表达水平,以β-肌动蛋白为内参;C:蛋白质印迹检测PTEN蛋白的表达水平,GAPDH为内参;D、E:蛋白质印迹检测Akt、p-Akt 和FAK蛋白(减少)的表达水平;F、G:qRT-PCR检测细胞中存活蛋白 mRNA的相对表达水平,以β-肌动蛋白为内参。在淋巴结侵袭性NSCLC H1299细胞中通过CRISPR Cas9技术敲低H1299细胞中的miR-29a/b/c后,蛋白质印迹检测存活蛋白蛋白的表达水平,GAPDH为内参;*:P<0.01
[1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
doi: 10.3322/caac.21492 URL |
[2] | Osmani L, Askin F, Gabrielson E, et al. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy[J]. Semin Cancer Biol, 2018, 52 Pt 1: 103-109. |
[3] |
Dai C, Ren Y, Xie D, et al. Does lymph node metastasis have a negative prognostic impact in patients with NSCLC and M1a disease[J]?. J Thorac Oncol, 2016, 11(10): 1745-1754.
doi: 10.1016/j.jtho.2016.06.030 URL |
[4] |
Worby CA, Dixon JE. PTEN[J]. Annu Rev Biochem, 2014, 83: 641-669.
doi: 10.1146/annurev-biochem-082411-113907 URL |
[5] |
Tang JM, He QY, Guo RX, et al. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis[J]. Lung Cancer, 2006, 51(2): 181-191.
doi: 10.1016/j.lungcan.2005.10.003 URL |
[6] | Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay[J]. Nat Rev Genet, 2010, 11(9): 597-610. |
[7] |
Liu H, Cheng L, Cao D, et al. Suppression of miR-21 expression inhibits cell proliferation and migration of liver cancer cells by targeting phosphatase and tensin homolog (PTEN)[J]. Med Sci Monit, 2018, 24: 3571-3577.
doi: 10.12659/MSM.907038 URL |
[8] | Lou Y, Yang X, Wang F, et al. MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein[J]. Int J Mol Med, 2010, 26(6): 819-827. |
[9] |
Feng X, Jiang J, Shi S, et al. Knockdown of miR-25 increases the sensitivity of liver cancer stem cells to TRAIL-induced apoptosis via PTEN/PI3K/Akt/Bad signaling pathway[J]. Int J Oncol, 2016, 49(6): 2600-2610.
doi: 10.3892/ijo.2016.3751 URL |
[10] |
Jing ZF, Bi JB, Li ZL, et al. miR-19 promotes the proliferation of clear cell renal cell carcinoma by targeting the FRK-PTEN axis[J]. Onco Targets Ther, 2019, 12: 2713-2727.
doi: 10.2147/OTT.S199238 URL |
[11] |
Kwon JJ, Factora TD, Dey S, et al. A systematic review of miR-29 in cancer[J]. Mol Ther Oncolytics, 2019, 12: 173-1794.
doi: 10.1016/j.omto.2018.12.011 URL |
[12] |
Robert J. Biology of cancer metastasis[J]. Bull Cancer, 2013, 100(4): 333-342.
doi: 10.1684/bdc.2013.1724 URL |
[13] |
Deng H, Wu RL, Zhou HY, et al. Significance of Survivin and PTEN expression in full lymph node-examined gastric cancer[J]. World J Gastroenterol, 2006, 12(7): 1013-1017.
doi: 10.3748/wjg.v12.i7.1013 URL |
[14] |
Wu Y, Song Y, Xiong Y, et al. MicroRNA-21 (Mir-21) promotes cell growth and invasion by repressing tumor suppressor PTEN in colorectal cancer[J]. Cell Physiol Biochem, 2017, 43(3): 945-958.
doi: 10.1159/000481648 URL |
[15] |
Feng C, Yao R, Huang F, et al. High level of PTEN expression is associated with low-grade liver metastasis and satisfactory patient survival in pancreatic cancer[J]. Arch Med Res, 2011, 42(7): 584-588.
doi: 10.1016/j.arcmed.2011.10.008 URL |
[16] |
Gkountakos A, Sartori G, Falcone I, et al. PTEN in lung cancer: dealing with the problem, building on new knowledge and turning the game around[J]. Cancers (Basel), 2019, 11(8): 1141.
doi: 10.3390/cancers11081141 URL |
[17] | Molinari F, Frattini M. Functions and regulation of the PTEN gene in colorectal cancer[J]. Front Oncol, 2013, 3: 326. |
[18] |
Kim DH, Suh J, Surh YJ, et al. Regulation of the tumor suppressor PTEN by natural anticancer compounds[J]. Ann N Y Acad Sci, 2017, 1401(1): 136-149.
doi: 10.1111/nyas.13422 URL |
[19] |
Lu J, Jeong HW, Kong N, et al. Stem cell factor SALL4 represses the transcriptions of PTEN and SALL1 through an epigenetic repressor complex[J]. PLoS One, 2009, 4(5): e5577.
doi: 10.1371/journal.pone.0005577 URL |
[20] |
Di Giorgio E, Clocchiatti A, Piccinin S, et al. MEF2 is a converging hub for histone deacetylase 4 and phosphatidylinositol 3-kinase/Akt-induced transformation[J]. Mol Cell Biol, 2013, 33(22): 4473-4491.
doi: 10.1128/MCB.01050-13 pmid: 24043307 |
[21] |
Poliseno L, Pandolfi PP. PTEN ceRNA networks in human cancer[J]. Methods, 2015, 77-78: 41-50.
doi: 10.1016/j.ymeth.2015.01.013 pmid: 25644446 |
[22] |
Jang SJ, Choi IS, Park G, et al. MicroRNA-205-5p is upregulated in myelodysplastic syndromes and induces cell proliferation via PTEN suppression[J]. Leuk Res, 2016, 47: 172-177.
doi: 10.1016/j.leukres.2016.06.003 URL |
[23] |
Yang Y, Guo JX, Shao ZQ. miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: an experimental study[J]. Asian Pac J Trop Med, 2017, 10(1): 87-91.
doi: S1995-7645(16)30448-5 pmid: 28107872 |
[24] |
Alizadeh M, Safarzadeh A, Beyranvand F, et al. The potential role of miR-29 in health and cancer diagnosis, prognosis, and therapy[J]. J Cell Physiol, 2019, 234(11): 19280-19297.
doi: 10.1002/jcp.28607 pmid: 30950056 |
[25] |
Ślusarz A, Pulakat L. The two faces of miR-29[J]. J Cardiovasc Med (Hagerstown), 2015, 16(7): 480-490.
doi: 10.2459/JCM.0000000000000246 URL |
No related articles found! |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||